Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Diagnostic Value of miR-1225-5p in Acute Coronary Syndrome and its Mechanism in ox-LDL Induced Human Coronary Artery Endothelial Cells Injury

Ju H., Si P., Li S., Yang D.

Prospective Study on Face & Skin, published in Clin Appl Thromb Hemost (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Clin Appl Thromb Hemost (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41757871
PMCID
PMC12954040
DOI
10.1177/10760296251414428

Abstract (original English)

BackgroundAcute coronary syndrome (ACS), a life-threatening cardiovascular emergency, faces challenges in early diagnosis and risk stratification. MicroRNAs (miRNAs) have emerged as key regulators in cardiovascular diseases.ObjectivesTo investigate the diagnostic/predictive significance of miR-1225-5p in ACS and its mechanism of regulating human coronary artery endothelial cells (HCAECs) injury induced by ox-LDL via targeting FAS.MethodsmiR-1225-5p levels in serum were determined by RT-qPCR in 99 ACS patients and controls, with correlation analysis to clinical indicators. HCAECs were used to assess viability, apoptosis, and inflammation/oxidative stress (IL-6, TNF-α, MDA, SOD) via CCK-8, flow cytometry, and ELISA. Target binding between FAS and miR-1225-5p was validated by dual-luciferase reporter and RIP assays, with functional validation experiments.ResultsmiR-1225-5p was significantly downregulated in ACS ( P NSTEMI > STEMI). ROC analysis showed high diagnostic accuracy (AUC = 0.885 for ACS; 0.790-0.964 for subtypes). miR-1225-5p (HR = 5.409, 95% CI = 1.281-22.837) and Gensini score (HR = 3.524, 95% CI = 1.066-11.646) acted as a predictive factor in ACS, and downregulated miR-1225-5p is linked to MACEs in ACS patients. Overexpression of miR-1225-5p alleviated ox-LDL-induced HCAECs injury (enhanced viability, suppressed apoptosis, reduced inflammation/oxidative stress). FAS a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Coronary VesselsEndothelial CellsHumansLipoproteins, LDLMicroRNAsApoptosisOxidative StressMiddle AgedFemaleMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research